September 5–8, 2012
Gordon Nelson, C(ASCP), NRCC-TC
Vice President, Chemistry Division
Managing Costs Associated with Chronic Pain by Early Detection of Patient Nonadherence and Cost-conscious Urine Drug Monitoring
Thursday, September 6, 10:45 a.m.
Friday, September 7, 4:00 p.m.
The requirements for conventional urine drug testing applications are different than for chronic pain management patients. This presentation will detail cost saving strategies for monitoring pain management patient adherence and propose clinical laboratory testing models.
Kamisha Johnson-Davis, PhD, DABCC
Medical Director, Clinical Toxicology Laboratory
Thursday, September 6, 4:00 p.m.
Friday, September 7, 10:45 a.m.
Urine is often the preferred specimen for drug testing due to noninvasive collection and because urine testing is readily available and inexpensive. However, pain management patients may adulterate or substitute urine to mimic compliance to drug therapy. This presentation will discuss strategies for detecting and preventing urine adulteration, as well as alternate specimen types that can be used for drug screening and which are less susceptible to adulteration/substitution.